US20030124075A1 - Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer - Google Patents

Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer Download PDF

Info

Publication number
US20030124075A1
US20030124075A1 US10/304,861 US30486102A US2003124075A1 US 20030124075 A1 US20030124075 A1 US 20030124075A1 US 30486102 A US30486102 A US 30486102A US 2003124075 A1 US2003124075 A1 US 2003124075A1
Authority
US
United States
Prior art keywords
copolymer
vinylimidazole
active principle
polymer
oxidation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/304,861
Inventor
Bruno Biatry
Eric Lheureux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Assigned to L'OREAL reassignment L'OREAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIATRY, BRUNO, LHEUREUX, ERIC
Publication of US20030124075A1 publication Critical patent/US20030124075A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/817Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90Block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/08Preparations for bleaching the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers

Definitions

  • the present invention relates to the use of a composition comprising at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer, preferably in a physiologically acceptable medium comprising an aqueous phase.
  • a composition comprising at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer, preferably in a physiologically acceptable medium comprising an aqueous phase.
  • the use is a cosmetic and/or dermatological use related to lightening or depigmenting the skin and/or the hair, and is thus preferably targeted to skin and/or hair to be lightened.
  • ascorbic acid stimulates the synthesis of the connective tissue and in particular of collagen, strengthens the defences of the cutaneous tissue against external attacks, such as ultraviolet radiation and pollution, compensates for vitamin E deficiency of the skin, depigments the skin and has a role in combatting free radicals.
  • these last two properties make it an excellent candidate as cosmetic or dermatological active principle for combatting ageing of the skin or for preventing ageing of the skin.
  • ascorbic acid is highly sensitive to certain environmental parameters and in particular to oxidation phenomena.
  • Another solution provided in the prior art consists in using a high concentration of glycols or polyols in order to reduce the solubility of oxygen in the formulation, thus protecting the ascorbic acid (WO 96/24325, EP 0 755 674, U.S. Pat. No. 5,981,578).
  • the polyols can optionally be incorporated in liposomes, as disclosed in U.S. Pat No. 6,020,367.
  • these solutions exhibit the disadvantage of resulting in sticky formulations, the cosmetic quality of which is difficult to improve.
  • the presence of a high concentration of these compounds can lead to phenomena of irritation.
  • Ascorbic acid can also be formulated in anhydrous media, such as silicones (U.S. Pat. No. 6,194,452), which are capable of creating an anhydrous barrier around ascorbic acid.
  • anhydrous media such as silicones (U.S. Pat. No. 6,194,452), which are capable of creating an anhydrous barrier around ascorbic acid.
  • composition employable in particular in the cosmetics field, in which a hydrophilic active principle which is unstable in an oxidizing medium is stabilized, which is comfortable on application, which does not lead to any skin irritation after application and which is compatible with the constraints of an industrial implementation of its manufacturing process.
  • One object of the present invention is to provide a composition comprising an oxidation-sensitive active principle selected from the group consisting of ascorbic acid and its derivatives, which exhibits good cosmetic properties, both with regard to touch and with regard to tolerance, the preservation of which over time does not require specific precautions, and which retains the depigmenting and/or lightening ability of the active principle.
  • N-vinylimidazole/N-vinylcaprolactam/N-vinylpyrrolidone copolymers are disclosed in U.S. Pat. No. 6,191,188. They are used in the manufacture of hair-strengthening compositions.
  • polymers or copolymers comprising N-vinylimidazole units have never been used in combination with hydrophilic active principles sensitive to decomposition by oxidation for the purpose of improving their stability in an aqueous medium. This is true in particular in the case of ascorbic acid.
  • One embodiment of the present invention is therefore the preferably cosmetic and/or dermatological use of a composition for depigmenting and/or lightening the skin and/or hair, including body hair, the composition comprising, preferably in a physiologically acceptable medium comprising an aqueous phase, at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and at least one non-crosslinked N-vinylimidazole polymer or copolymer, the active principle and the polymer or copolymer both being present in the aqueous phase.
  • the copolymer is preferably present in an amount sufficient to stabilize the said oxidation-sensitive hydrophilic active principle.
  • composition furthermore exhibits the advantage of acting both by inhibiting tyrosinase, thus reducing melanogenesis, and also by inhibiting the dendricity of melanocytes.
  • the depigmenting effect thus obtained is much greater than that obtained, for example, with ascorbic acid alone, which acts solely on melanogenesis.
  • Another embodiment of the present invention is the use of a combination composed of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer, the active principle and the polymer or copolymer both being in the aqueous phase, in a cosmetic composition, as depigmenting agent.
  • hydrophilic active principle is understood to mean a compound having a solubility in water of at least 0.25% at ambient temperature (25° C.).
  • the term “oxidation-sensitive hydrophilic active principle” is understood to mean any active principle of natural or synthetic origin capable of undergoing decomposition by an oxidation mechanism. This oxidation phenomenon can have several causes, in particular the presence of oxygen, of light or of metal ions, a high temperature or certain pH conditions.
  • ascorbic acid and its derivatives such as salts and esters thereof, particularly the 5,6-di-O-dimethylsilylascorbate (sold by Exsymol under the reference PRO-AA), the potassium salt of dl- ⁇ -tocopheryl dl-ascorbyl phosphate (sold by Senju Pharmaceutical under the reference SEPIVITAL EPC), magnesium ascorbyl phosphate or sodium ascorbyl phosphate (sold by Roche under the reference Stay-C 50).
  • ascorbic acid and its derivatives such as salts and esters thereof, particularly the 5,6-di-O-dimethylsilylascorbate (sold by Exsymol under the reference PRO-AA), the potassium salt of dl- ⁇ -tocopheryl dl-ascorbyl phosphate (sold by Senju Pharmaceutical under the reference SEPIVITAL EPC), magnesium ascorbyl phosphate or sodium ascorbyl phosphate (sold by Roche under the reference Stay-C 50).
  • the oxidation-sensitive hydrophilic active principle is ascorbic acid.
  • Other preferred principles meet the above requirements and possess the ability to lighten the skin and/or the hair.
  • the oxidation sensitive hydrophilic active principle is preferably present in an amount sufficient to lighten the hair and/or skin, which amount is determinable by one of ordinary skill without undue effort.
  • Example amounts include 1-10% based on total weight.
  • non-crosslinked N-vinylimidazole polymer or copolymer is understood to mean any polymer comprising N-vinylimidazole units and not comprising a crosslinking agent.
  • Copolymers suitable for the implementation of the invention are copolymers combining N-vinylimidazole with N-vinylpyrrolidone and/or N-vinylcaprolactam subunits.
  • the copolymer has a molar fraction of N-vinylimidazole units of between 0.1 and 1, more preferably between 0.4 and 0.9.
  • the molar ratio of the N-vinylimidazole unit equivalent to the oxidation-sensitive hydrophilic active principle varies between 0.004 and 16 and preferably between 0.01 and 1.
  • Use is preferably made of an N-vinylimidazole/N-vinylpyrrolidone copolymer.
  • the weight-average molar mass of the N-vinylimidazole polymers is preferably between 1 000 and 1 ⁇ 10 7 and more preferably between 5 000 and 5 ⁇ 10 6 .
  • Use may be made, to this end, of the vinylpyrrolidone/vinylimidazole (50/50) copolymer having a weight-average molar mass of 1 200 000 sold under the reference LUVITEC VPI 55K72W by BASF or the vinylpyrrolidone/vinylimidazole (50/50) copolymer having a weight-average molar mass of 10 000 sold under the reference LUVITEC VPI 55K18P by BASF.
  • the polymers or copolymers according to the invention can, for example, be prepared according to the method disclosed in Patent Application WO-97/45517.
  • the at least one polymer or copolymer is preferably present in the composition according to the invention in an amount sufficient to produce the desired effect, that is to say in an amount sufficient to stabilize the oxidation-sensitive hydrophilic active principle.
  • the polymer or copolymer is present at a concentration of between 0.1 and 5% by weight with respect to the total weight of the aqueous phase and more particularly at a concentration of between 0.1 and 2% by weight with respect to the total weight of the aqueous phase.
  • compositions used according to the invention are preferably intended for topical application to the skin and/or its superficial body growths and therefore comprise a physiologically acceptable medium, that is to say a medium compatible with cutaneous tissues, such as the skin, scalp, eyelashes, eyebrows, hair, nails and mucous membranes.
  • This physiologically acceptable medium comprises at least one aqueous phase and optionally a physiologically acceptable organic solvent chosen, for example, from lower alcohols comprising from 1 to 8 carbon atoms and in particular from 1 to 6 carbon atoms, such as ethanol, isopropanol, propanol or butanol; polyethylene glycols having from 6 to 80 ethylene oxide units; or polyols, such as propylene glycol, isoprene glycol, butylene glycol, glycerol or sorbitol.
  • a physiologically acceptable organic solvent chosen, for example, from lower alcohols comprising from 1 to 8 carbon atoms and in particular from 1 to 6 carbon atoms, such as ethanol, isopropanol, propanol or butanol; polyethylene glycols having from 6 to 80 ethylene oxide units; or polyols, such as propylene glycol, isoprene glycol, butylene glycol, glycerol or sorbitol.
  • the physiologically acceptable medium is an aqueous medium, it generally has a pH which is compatible with the skin, preferably ranging from 3 to 9 and better still from 3.5 to 7.5.
  • compositions according to the invention can be provided in any form, including any pharmaceutical dosage form used for topical application and in particular in the form of aqueous or aqueous/alcoholic solutions, of oil-in-water (O/W) or water-in-oil (W/O) or multiple (triple: W/O/W or O/W/O) emulsions, of aqueous gels or of dispersions of a fatty phase in an aqueous phase using spherules, it being possible for these spherules to be polymeric nanoparticles, such as nanospheres and nanocapsules, or lipid vesicles of ionic and/or nonionic type (liposomes, niosomes or oleosomes). These compositions are prepared according to the usual methods.
  • compositions used according to the invention can be more or less fluid and can have the appearance of a white or coloured cream, of an ointment, of a milk, of a lotion, of a serum, of a paste or of a foam. They can optionally be applied to the skin in the form of an aerosol. They can also be provided in a solid form, for example in the form of a stick.
  • composition used according to the invention comprises an oily phase
  • the latter preferably comprises at least one oil. It can additionally comprise other fatty substances.
  • oils which can be used in the composition of the invention of, for example:
  • hydrocarbonaceous oils of animal origin such as perhydrosqualene
  • hydrocarbonaceous oils of vegetable origin such as liquid triglycerides of fatty acids comprising from 4 to 10 carbon atoms, such as triglycerides of heptanoic acid or octanoic acid, or alternatively, for example, sunflower, maize, soybean, gourd, grape seed, sesame, hazelnut, apricot, macadamia, arara, castor or avocado oils, triglycerides of caprylic/capric acids, such as those sold by Stéarineries Dubois or those sold under the names Miglyol 810, 812 and 818 by Dynamit Nobel, jojoba oil, or karite butter oil;
  • esters and ethers in particular of fatty acids, such as the oils of formulae R 1 COOR 2 and R 1 OR 2 in which R 1 represents the residue of a fatty acid comprising from 8 to 29 carbon atoms and R 2 represents a branched or unbranched hydrocarbonaceous chain comprising from 3 to 30 carbon atoms, such as, for example, purcellin oil, isononyl isononanoate, isopropyl myristate, 2-ethylhexyl palmitate, 2-octyldodecyl stearate, 2-octyldodecyl erucate or isostearyl isostearate; hydroxylated esters, such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate or heptanoates, octano
  • linear or branched hydrocarbons of mineral or synthetic origin such as volatile or nonvolatile liquid paraffins and their derivatives, liquid petrolatum, polydecenes or hydrogenated polyisobutene, such as sesam oil;
  • fatty alcohols having from 8 to 26 carbon atoms such as cetyl alcohol, stearyl alcohol and their mixture (cetearyl alcohol), octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleyl alcohol or linoleyl alcohol;
  • silicone oils such as volatile or nonvolatile polymethylsiloxanes (PDMS) comprising a linear or cyclic silicone chain which are liquid or pasty at ambient temperature, in particular cyclopolydimethylsiloxanes (cyclomethicones), such as cyclohexasiloxane; polydimethylsiloxanes comprising pendent alkyl, alkoxy or phenyl groups or alkyl, alkoxy or phenyl groups at the end of the silicone chain, which groups have from 2 to 24 carbon atoms; or phenylated silicones, such as phenyl trimethicones, phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes, (2-phenylethyl)trimethylsiloxysilicates and polymethylphenylsiloxanes;
  • PDMS volatile or nonvol
  • hydrocarbonaceous oil is understood to mean, in the list of the oils mentioned above, any oil predominantly comprising carbon and hydrogen atoms and optionally ester, ether, fluorinated, carboxylic acid and/or alcohol groups.
  • the other fatty substances which can be present in the oily phase are, for example, fatty acids comprising from 8 to 30 carbon atoms, such as stearic acid, lauric acid, palmitic acid and oleic acid; waxes, such as lanolin, beeswax, carnauba or candelilla wax, paraffin or lignite waxes or microcrystalline waxes, ceresin or ozokerite, or synthetic waxes, such as polyethylene waxes or Fischer-Tropsch waxes; silicone resins, such as trifluoromethyl C 1-4 alkyl dimethicone and trifluoropropyl dimethicone; and silicone elastomers, such as the products sold under the names “KSG” by Shin-Etsu, under the names “Trefil”, “BY29” or “EPSX” by Dow Corning or under the names “Gransil” by Grant Industries.
  • fatty acids comprising from 8 to 30 carbon atoms, such as stea
  • fatty substances can be chosen in a way varied by a person skilled in the art in order to prepare a composition having the desired properties, for example of consistency or of texture, in view of this disclosure.
  • the composition according to the invention is a water-in-oil (W/O) or oil-in-water (O/W) emulsion.
  • W/O water-in-oil
  • O/W oil-in-water
  • the proportion of the oily phase in the emulsion can range from 5 to 80% by weight and preferably from 5 to 50% by weight with respect to the total weight of the composition.
  • the emulsions generally preferably comprise at least one emulsifier selected from the group consisting of amphoteric, anionic, cationic or nonionic emulsifiers, used alone or as a mixture, and optionally a coemulsifier.
  • the emulsifiers are appropriately chosen according to the emulsion to be obtained (W/O or O/W).
  • the emulsifier and the coemulsifier are generally preferably present in the composition in a proportion ranging from 0.3 to 30% by weight and preferably from 0.5 to 20% by weight with respect to the total weight of the composition.
  • W/O emulsions for example, as emulsifiers, of dimethicone copolyols, such as the mixture of cyclomethicone and of dimethicone copolyol sold under the name “DC 5225 C” by Dow Corning, and alkyl dimethicone copolyols, such as the laurylmethicone copolyol sold under the name “Dow Corning 5200 Formulation Aid” by Dow Coming and the cetyl dimethicone copolyol sold under the name Abil EM 90 R by Goldschmidt.
  • dimethicone copolyols such as the mixture of cyclomethicone and of dimethicone copolyol sold under the name “DC 5225 C” by Dow Corning
  • alkyl dimethicone copolyols such as the laurylmethicone copolyol sold under the name “Dow Corning 5200 Formulation Aid” by Dow Coming and the cetyl
  • Use may also be made, as surfactant of W/O emulsions, of a crosslinked solid organopolysiloxane elastomer comprising at least one oxyalkylenated group, such as those obtained according to the procedure of Examples 3, 4 and 8 of the document U.S. Pat. No. 5,412,004 and the examples of the document U.S. Pat. No. 5,811,487, in particular the product of Example 3 (synthetic example) of U.S. Pat. No. 5,412,004, and such as that sold under the reference KSG 21 by Shin Etsu.
  • Use may also be made, as emulsifier, of a polyolefin-derived oligomer or polymer comprising a succinic ending; the latter is preferably a polyolefin comprising an esterified or amidated succinic ending or a salt of such a polyolefin and in particular polyisobutylene comprising an esterified or amidated succinic ending such as the products sold under the names L5603 and L2721 and OS131769 by Lubrizol.
  • O/W emulsions for example, as emulsifiers, of nonionic emulsifiers, such as esters of fatty acids and of glycerol which are oxyalkylenated (more particularly polyoxyethylenated); esters of fatty acids and of sorbitan which are oxyalkylenated; esters of fatty acids which are oxyalkylenated (oxyethylenated and/or oxypropylenated); ethers of fatty alcohols which are oxyethylenated (oxyethylenated and/or oxypropylenated); sugar esters, such as sucrose stearate; and their mixtures, such as the mixture of glyceryl stearate and of PEG-40 stearate.
  • nonionic emulsifiers such as esters of fatty acids and of glycerol which are oxyalkylenated (more particularly polyoxyethylenated); esters of fatty acids
  • the cosmetic or dermatological composition of the invention can also comprise adjuvants known in the cosmetics or dermatological field, such as hydrophilic or lipophilic gelling agents, preservatives, solvents, fragrances, fillers, UV screening agents, bactericides, odour absorbers, colouring materials, plant extracts or salts.
  • adjuvants known in the cosmetics or dermatological field, such as hydrophilic or lipophilic gelling agents, preservatives, solvents, fragrances, fillers, UV screening agents, bactericides, odour absorbers, colouring materials, plant extracts or salts.
  • the amounts of these various adjuvants are those generally used in the field under consideration, for example from 0.01 to 20% of the total weight of the composition.
  • These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase and/or into the lipid spherules.
  • fillers which can be used in the composition of the invention, for example, of pigments, silica powder; talc; particles of polyamide and in particular those sold under the name Orgasol by Atochem; polyethylene powders; microspheres based on acrylic copolymers, such as those made of ethylene glycol dimethacrylate/lauryl methacrylate copolymer which are sold by Dow Corning under the name Polytrap; expanded powders, such as hollow microspheres and in particular the microspheres sold under the name Expancel by Kemanord Plast or under the name Micropearl F 80 ED by Matsumoto; silicone resin microbeads, such as those sold under the name Tospearl by Toshiba Silicone; and their mixtures.
  • These fillers can be present in amounts ranging from 0 to 20% by weight and preferably from 1 to 10% by weight with respect to the total weight of the composition.
  • compositions in accordance with the invention can additionally comprise at least one organic photoprotective agent and/or at least one inorganic photoprotective agent which is active in the UV-A and/or UV-B regions (absorbers), and which are soluble in water or in fats or else are insoluble in the cosmetic solvents commonly used.
  • at least one organic photoprotective agent and/or at least one inorganic photoprotective agent which is active in the UV-A and/or UV-B regions (absorbers), and which are soluble in water or in fats or else are insoluble in the cosmetic solvents commonly used.
  • organic photoprotective agents are chosen in particular from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives; camphor derivatives; triazine derivatives, such as those disclosed in Patent Applications U.S. Patent No.
  • PABA p-aminobenzoic acid
  • salicylic derivatives in particular homosalate (sold under the name “Eusolex HMS” by Rona/EM Industries), ethylhexyl salicylate (sold under the name “Neo Heliopan OS” by Haarmann and Reimer), dipropylene glycol salicylate (sold under the name “Dipsal” by Scher), or TEA salicylate (sold under the name “Neo Heliopan TS” by Haarmann and Reimer),
  • dibenzoylmethane derivatives in particular butyl methoxydibenzoylmethane (sold in particular under the trade name “Parsol 1789” by Hoffmann-LaRoche), or isopropyl dibenzoylmethane,
  • cinnamic derivatives in particular ethylhexyl methoxycinnamate (sold in particular under the trade name “Parsol MCX” by Hoffmann-LaRoche), isopropyl methoxycinnamate, isoamyl methoxycinnamate (sold under the trade name “Neo Heliopan E 1000” by Haarmann and Reimer), cinoxate, DEA methoxycinnamate, diisopropyl methyl cinnamate, or glyceryl ethylhexanoate dimethoxycinnamate,
  • ⁇ , ⁇ -diphenylacrylate derivatives in particular octocrylene (sold in particular under the trade name “Uvinul N539” by BASF) or etocrylene (sold in particular under the trade name “Uvinul N35” by BASF),
  • benzophenone in particular benzophenone-1 (sold under the trade name “Uvinul 400” by BASF), benzophenone-2 (sold under the trade name “Uvinul D50” by BASF), benzophenone-3 or oxybenzone (sold under the trade name “Uvinul M40” by BASF), benzophenone-4 (sold under the trade name “Uvinul MS40” by BASF), benzophenone-5, benzophenone-6 (sold under the trade name “Helisorb 11” by Norquay), benzophenone-8 (sold under the trade name “Spectra-Sorb UV-24” by American Cyanamid), benzophenone-9 (sold under the trade name “Uvinul DS-49” by BASF), benzophenone-12, or n-hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate,
  • benzylidene camphor derivatives in particular 3-benzylidene camphor (manufactured under the name “Mexoryl SD” by Chimex), 4-methylbenzylidene camphor (sold under the name “Eusolex 6300” by Merck), benzylidene camphor sulphonic acid (manufactured under the name “Mexoryl SL” by Chimex), camphor benzalkonium methosulphate (manufactured under the name “Mexoryl SO” by Chimex), terephthalylidene dicamphor sulphonic acid (manufactured under the name “Mexoryl SX” by Chimex), or polyacrylamidomethyl benzylidene camphor (manufactured under the name “Mesoryl SW” by Chimex),
  • benzimidazole derivatives in particular phenylbenzimidazole sulphonic acid (sold in particular under the trade name “Eusolex 232” by Merck), or disodium phenyl dibenzimidazole tetrasulphonate (sold under the trade name “Neo Heliopan AP” by Haarmann and Reimer),
  • triazine derivatives in particular anisotriazine (sold under the trade name “Tinosorb S” by Ciba Specialty Chemicals), ethylhexyl triazone (sold in particular under the trade name “Uvinul T150” by BASF), diethylhexyl butamido triazone (sold under the trade name “Uvasorb HEB” by Sigma 3V) or 2,4,6-tris(diisobutyl 4′-amino-benzalmalonate)-s-triazine,
  • benzotriazole derivatives in particular drometrizole trisiloxane (sold under the name “Silatrizole” by Rhodia Chimie) or methylene bisbenzotriazolyl tetramethylbutylphenol (sold in the solid form under the trade name “Mixxim BB/100” by Fairmount Chemical or in the micronized form in aqueous dispersion under the trade name “Tinosorb M” by Ciba Specialty Chemicals),
  • anthranilic derivatives in particular menthyl anthranilate (sold under the trade name “Neo Heliopan MA” by Haarmann and Reimer),
  • imidazoline derivatives in particular ethylhexyl dimethoxybenzylidene dioxoimidazoline propionate,
  • benzalmalonate derivatives in particular polyorganosiloxane comprising benzalmalonate functional groups (sold under the trade name “Parsol SLX” by Hoffmann-LaRoche),
  • the organic photoprotective agents which are more particularly preferred are selected from the group consisting of ethylhexyl salicylate, ethylhexyl methoxycinnamate, octocrylene, phenylbenzimidazole sulphonic acid, benzophenone-3, benzophenone-4, benzophenone-5, 4-methylbenzylidene camphor, terephthalylidene dicamphor sulphonic acid, disodium phenyl dibenzimidazole tetrasulphonate, 2,4,6-tris(diisobutyl 4′-aminobenzalmalonate)-s-triazine, anisotriazine, ethylhexyl triazone, diethylhexyl butamido triazone, methylene bisbenzotriazolyl tetramethylbutylphenol, drometrizole trisiloxane, 1,1′-dicarbox
  • the inorganic photoprotective agents may be selected from the group consisting of pigments or alternatively nanopigments (mean size of the primary particles: generally between 5 nm and 100 nm, preferably between 10 nm and 50 nm) formed from coated or uncoated metal oxides, such as, for example, titanium oxide (amorphous or crystalline in the rutile and/or anatase form), iron oxide, zinc oxide, zirconium oxide or cerium oxide nanopigments, which are all UV photoprotective agents well known per se.
  • Conventional coating agents are, furthermore, alumina and/or aluminium stearate.
  • Such nanopigments formed from coated or uncoated metal oxides are disclosed in particular in Patent Applications EP 518 772 and EP 518 773.
  • the photoprotective agents are generally present in the compositions according to the invention in proportions ranging from 0.1 to 20% by weight with respect to the total weight of the composition and preferably ranging from 0.2 to 15% by weight with respect to the total weight of the composition.
  • composition used can additionally comprise at least one other depigmenting or anti-pigmentation active principle in addition to the hydrophilic active principle mentioned above.
  • the depigmenting or anti-pigmentation agents capable of being incorporated in the composition according to the present invention include, for example, the following compounds: kojic acid; ellagic acid; arbutin and its derivatives, such as those disclosed in Applications EP-895 779 and EP-524 109; hydroquinone; aminophenol derivatives, such as those disclosed in Applications WO 99/10318 and WO 99/32077, in particular N-cholesteryloxycarbonyl-para-aminophenol and N-ethyloxycarbonyl-para-aminophenol; iminophenol derivatives, in particular those disclosed in Application WO 99/22707; L-2-oxothiazolidine-4-carboxylic acid or procysteine, and its salts and esters; ascorbic acid and its derivatives, in particular ascorbyl glucoside and magnesium ascorbyl phosphate; 4-butylresorcinol or lucinol; thiourea and its derivatives; calcium D-pante
  • composition according to the invention can be applied to, for example, the skin, hair, including body hair, eyelashes, nails or lips. It can thus be used in a cosmetic treatment process for depigmenting and/or lightening the skin and/or hair, including body hair, comprising the application of the composition according to the invention to the skin and/or hair, including body hair
  • composition according to the invention can be used for the manufacture of a dermatological preparation comprising an aqueous phase which is intended to depigment the skin and/or hair, including body hair.
  • the aim of this test is to study the decomposition of an oxidation-sensitive hydrophilic active principle after storing for two months at 45° C.
  • Various solutions were prepared and their compositions are collated in the following table: TABLE I Compositions (in Solution A water) (Control) Solution B Solution C Solution D Ascorbic acid 15% 15% 15% 15% 15% 15% Polymer 1 — 1% — — Polymer 2 — — 1% — Polymer 3 — — — 1%
  • Polymer 1 Vinylpyrrolidone/vinylimidazole (50/50) copolymer sold under the reference Luvitec VPI 55K72W of BASF (Weight-average molecular mass 1.2 ⁇ 10 6 ).
  • Polymer 2 Vinylpyrrolidone/vinylimidazole (50/50) copolymer sold under the reference Luvitec VPI 55K18P of BASF (Weight-average molecular mass 10 000).
  • Polymer 3 Polyvinylpyrrolidone sold under the reference Kollidon 12PF of BASF (Weight-average molecular mass 3 000).
  • the concentration of ascorbic acid is determined by the HPLC technique (LaChrom Merck system).
  • the analytical conditions are as follows:
  • the aim of this test is to show the effect of the combination of ascorbic acid with a polymer or copolymer according to the invention on adjusting the melanogenesis of human keratinocyte-melanocyte cocultures.
  • the melanocytes are labelled using the NK1beteb antibody (green colouring), which recognizes the melanosomes at every stage of maturation.
  • the nuclei of all the cells, melanocytes and keratinocytes, are stained using propidium iodide (red colouring).
  • composition is prepared in a way conventional to a person skilled in the art.
  • B Demineralized water 60.53 g Glycerol 3 g Ascorbic acid 5 g 50% Potassium hydroxide 3.07 g Vinylpyrrolidone/vinylimidazole copolymer 1 g Preservative 0.2 g C Fragrance 0.1 g
  • a fresh gel is obtained, which gel makes it possible to combat cutaneous blemishes and in which gel ascorbic acid has good stability.
  • compositions comprising, in a physiologically acceptable medium comprising an aqueous phase, at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of, e.g., ascorbic acid and its derivatives, and at least one non-crosslinked N-vinylimidazole polymer or copolymer, the said active principle and the said polymer or copolymer both being in the aqueous phase.
  • a combination composed of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer in the aqueous phase of a cosmetic composition as agent for lightening the skin and/or hair, including body hair.
  • this invention makes available the use of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer for the preparation of a dermatological composition comprising an aqueous phase which is intended to depigment the skin and/or hair, including body hair.
  • a combination composed of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer in the aqueous phase of a cosmetic composition as agent for lightening the skin and/or hair, including body hair, and the use of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer for the preparation of a dermatological composition comprising an aqueous phase which is intended to depigment the skin and/or hair, including body hair.
  • a preferred embodiment of the invention fully described and made available herein is a method for lightening the skin and/or hair, comprising applying thereto a composition comprising a physiologically acceptable medium comprising an aqueous phase; at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives, and at least one non-crosslinked N-vinylimidazole polymer or copolymer, the active principle and the polymer or copolymer both being present in the aqueous phase.
  • French patent application 0115375 is hereby incorporated by reference, as are all references, texts, documents, standards, applications, patents, etc., mentioned above.

Abstract

The invention relates to the use of a composition contains at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and at least one non-crosslinked N-vinylimidazole polymer or copolymer, the active principle and the said polymer or copolymer both being in the aqueous phase, for lightening and/or depigmenting the skin and/or hair, including body hair.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0001]
  • The present invention relates to the use of a composition comprising at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer, preferably in a physiologically acceptable medium comprising an aqueous phase. Preferably the use is a cosmetic and/or dermatological use related to lightening or depigmenting the skin and/or the hair, and is thus preferably targeted to skin and/or hair to be lightened. [0002]
  • 2. Background of the Invention [0003]
  • It is known to introduce, into cosmetic compositions, various active principles intended to contribute specific treatments to the skin and/or hair. However, some of these active principles exhibit the disadvantage of being unstable in an aqueous medium and of easily decomposing on contact with water, in particular because of oxidation phenomena. They thus rapidly lose their activity over time and this instability conflicts with the desired effectiveness. [0004]
  • Attempts have thus been made for a long time to formulate ascorbic acid or vitamin C because of its numerous beneficial properties. In particular, ascorbic acid stimulates the synthesis of the connective tissue and in particular of collagen, strengthens the defences of the cutaneous tissue against external attacks, such as ultraviolet radiation and pollution, compensates for vitamin E deficiency of the skin, depigments the skin and has a role in combatting free radicals. These last two properties make it an excellent candidate as cosmetic or dermatological active principle for combatting ageing of the skin or for preventing ageing of the skin. Unfortunately, because of its chemical structure (of α-ketolactone), ascorbic acid is highly sensitive to certain environmental parameters and in particular to oxidation phenomena. There thus ensues rapid decomposition of formulated ascorbic acid in the presence of these parameters and in particular in the presence of oxygen, light or metal ions, as a function of the temperature or under certain pH conditions (Pharm. Acta. Helv., 1969, 44, 611-667; STP Pharma, 1985, 4, 281-286). [0005]
  • Several solutions have thus been envisaged in the prior art for reducing and/or slowing down the decomposition of ascorbic acid. [0006]
  • Provision has thus been made to use ascorbic acid in the form of a chemical derivative (magnesium ascorbyl phosphate or esters of fatty acids and ascorbic acid), but the bioavailability of these derivatives is very low (J. Am. Acad. Dermatol., 1996, 34, 29-33). [0007]
  • The instability of ascorbic acid with respect to oxygen can be improved by using specific packagings, such as twin compartments under an inert atmosphere, as disclosed in U.S. Pat. No. 5,935,584, or alternatively by the use of two-phase emulsions, one phase of which is composed of a dry powder comprising ascorbic acid and the second phase of which is a liquid phase. The mixing of the two phases has to be carried out at the time of use (WO 98/43598). These solutions have disadvantages with regard to the cost and the complexity of the manufacturing operations and significant restrictions with regard to use. [0008]
  • Another solution provided in the prior art consists in using a high concentration of glycols or polyols in order to reduce the solubility of oxygen in the formulation, thus protecting the ascorbic acid (WO 96/24325, EP 0 755 674, U.S. Pat. No. 5,981,578). The polyols can optionally be incorporated in liposomes, as disclosed in U.S. Pat No. 6,020,367. However, these solutions exhibit the disadvantage of resulting in sticky formulations, the cosmetic quality of which is difficult to improve. Furthermore, the presence of a high concentration of these compounds can lead to phenomena of irritation. [0009]
  • Ascorbic acid can also be formulated in anhydrous media, such as silicones (U.S. Pat. No. 6,194,452), which are capable of creating an anhydrous barrier around ascorbic acid. A major disadvantage of such solutions results from the lack of freshness on application. [0010]
  • The need thus remains for a composition employable in particular in the cosmetics field, in which a hydrophilic active principle which is unstable in an oxidizing medium is stabilized, which is comfortable on application, which does not lead to any skin irritation after application and which is compatible with the constraints of an industrial implementation of its manufacturing process. [0011]
  • The activity of ascorbic acid or of its derivatives on pigmentation has been known for many years. Various mechanisms have been described to explain their effect on the reduction of melanogenesis. The inhibiting effect on tyrosinase has been demonstrated for ascorbic acid (J. Soc. Cosmet. Chem., 42, 1991, p. 361-368). Some of its esters have been used for some years in depigmenting treatments, that is to say, magnesium ascorbyl phosphate and ascorbyl glucoside. More recently, a study has shown that magnesium ascorbyl phosphate can reduce the dendricity of melanocytes (Pigment. Cell. Res., 13, 2000, p. 89-98 and p. 190-192). [0012]
  • OBJECTS OF THE INVENTION
  • One object of the present invention is to provide a composition comprising an oxidation-sensitive active principle selected from the group consisting of ascorbic acid and its derivatives, which exhibits good cosmetic properties, both with regard to touch and with regard to tolerance, the preservation of which over time does not require specific precautions, and which retains the depigmenting and/or lightening ability of the active principle. [0013]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The Inventors have discovered that the use of non-crosslinked N-vinylimidazole polymers or copolymers in compositions in which the aqueous phase includes an oxidation-sensitive active principle, such as ascorbic acid, makes it possible to achieve the abovementioned object. [0014]
  • In the prior art, some compounds having an imidazole structure have been disclosed for their stabilizing properties. Thus, in Patent Application EP 0 586 106, several imidazole-based molecules are used to stabilize certain retinoids against chemical decomposition. Furthermore, polymeric emulsifiers composed of N-vinylimidazole, of alkyl acrylates and of vinyl acetates are disclosed in U.S. Pat. No. 4,057,622. They are used for the purpose of replacing known emulsifiers in order to overcome their disadvantages, in particular with regard to smell, and to stabilize water-in-oil emulsions. Finally, N-vinylimidazole/N-vinylcaprolactam/N-vinylpyrrolidone copolymers are disclosed in U.S. Pat. No. 6,191,188. They are used in the manufacture of hair-strengthening compositions. [0015]
  • To the knowledge of the inventors, polymers or copolymers comprising N-vinylimidazole units have never been used in combination with hydrophilic active principles sensitive to decomposition by oxidation for the purpose of improving their stability in an aqueous medium. This is true in particular in the case of ascorbic acid. [0016]
  • One embodiment of the present invention is therefore the preferably cosmetic and/or dermatological use of a composition for depigmenting and/or lightening the skin and/or hair, including body hair, the composition comprising, preferably in a physiologically acceptable medium comprising an aqueous phase, at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and at least one non-crosslinked N-vinylimidazole polymer or copolymer, the active principle and the polymer or copolymer both being present in the aqueous phase. The copolymer is preferably present in an amount sufficient to stabilize the said oxidation-sensitive hydrophilic active principle. [0017]
  • The use of such a composition furthermore exhibits the advantage of acting both by inhibiting tyrosinase, thus reducing melanogenesis, and also by inhibiting the dendricity of melanocytes. The depigmenting effect thus obtained is much greater than that obtained, for example, with ascorbic acid alone, which acts solely on melanogenesis. [0018]
  • Another embodiment of the present invention is the use of a combination composed of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer, the active principle and the polymer or copolymer both being in the aqueous phase, in a cosmetic composition, as depigmenting agent. [0019]
  • According to the invention, the term “hydrophilic active principle” is understood to mean a compound having a solubility in water of at least 0.25% at ambient temperature (25° C.). [0020]
  • According to the invention, the term “oxidation-sensitive hydrophilic active principle” is understood to mean any active principle of natural or synthetic origin capable of undergoing decomposition by an oxidation mechanism. This oxidation phenomenon can have several causes, in particular the presence of oxygen, of light or of metal ions, a high temperature or certain pH conditions. [0021]
  • Mention may be made, by way of example and without implied limitation, of: ascorbic acid and its derivatives, such as salts and esters thereof, particularly the 5,6-di-O-dimethylsilylascorbate (sold by Exsymol under the reference PRO-AA), the potassium salt of dl-α-tocopheryl dl-ascorbyl phosphate (sold by Senju Pharmaceutical under the reference SEPIVITAL EPC), magnesium ascorbyl phosphate or sodium ascorbyl phosphate (sold by Roche under the reference Stay-C 50). [0022]
  • In a particularly advantageous aspect, the oxidation-sensitive hydrophilic active principle is ascorbic acid. Other preferred principles meet the above requirements and possess the ability to lighten the skin and/or the hair. [0023]
  • The oxidation sensitive hydrophilic active principle is preferably present in an amount sufficient to lighten the hair and/or skin, which amount is determinable by one of ordinary skill without undue effort. Example amounts include 1-10% based on total weight. [0024]
  • According to the invention, the term “non-crosslinked N-vinylimidazole polymer or copolymer” is understood to mean any polymer comprising N-vinylimidazole units and not comprising a crosslinking agent. Copolymers suitable for the implementation of the invention are copolymers combining N-vinylimidazole with N-vinylpyrrolidone and/or N-vinylcaprolactam subunits. [0025]
  • In an advantageous aspect of the invention, the copolymer has a molar fraction of N-vinylimidazole units of between 0.1 and 1, more preferably between 0.4 and 0.9. [0026]
  • According to an advantageous aspect of the invention, the molar ratio of the N-vinylimidazole unit equivalent to the oxidation-sensitive hydrophilic active principle varies between 0.004 and 16 and preferably between 0.01 and 1. [0027]
  • Use is preferably made of an N-vinylimidazole/N-vinylpyrrolidone copolymer. [0028]
  • The weight-average molar mass of the N-vinylimidazole polymers is preferably between 1 000 and 1×10[0029] 7 and more preferably between 5 000 and 5×106.
  • Use may be made, to this end, of the vinylpyrrolidone/vinylimidazole (50/50) copolymer having a weight-average molar mass of 1 200 000 sold under the reference LUVITEC VPI 55K72W by BASF or the vinylpyrrolidone/vinylimidazole (50/50) copolymer having a weight-average molar mass of 10 000 sold under the reference LUVITEC VPI 55K18P by BASF. The polymers or copolymers according to the invention can, for example, be prepared according to the method disclosed in Patent Application WO-97/45517. [0030]
  • The at least one polymer or copolymer is preferably present in the composition according to the invention in an amount sufficient to produce the desired effect, that is to say in an amount sufficient to stabilize the oxidation-sensitive hydrophilic active principle. Preferably, the polymer or copolymer is present at a concentration of between 0.1 and 5% by weight with respect to the total weight of the aqueous phase and more particularly at a concentration of between 0.1 and 2% by weight with respect to the total weight of the aqueous phase. [0031]
  • The compositions used according to the invention are preferably intended for topical application to the skin and/or its superficial body growths and therefore comprise a physiologically acceptable medium, that is to say a medium compatible with cutaneous tissues, such as the skin, scalp, eyelashes, eyebrows, hair, nails and mucous membranes. This physiologically acceptable medium comprises at least one aqueous phase and optionally a physiologically acceptable organic solvent chosen, for example, from lower alcohols comprising from 1 to 8 carbon atoms and in particular from 1 to 6 carbon atoms, such as ethanol, isopropanol, propanol or butanol; polyethylene glycols having from 6 to 80 ethylene oxide units; or polyols, such as propylene glycol, isoprene glycol, butylene glycol, glycerol or sorbitol. [0032]
  • When the physiologically acceptable medium is an aqueous medium, it generally has a pH which is compatible with the skin, preferably ranging from 3 to 9 and better still from 3.5 to 7.5. [0033]
  • The compositions according to the invention can be provided in any form, including any pharmaceutical dosage form used for topical application and in particular in the form of aqueous or aqueous/alcoholic solutions, of oil-in-water (O/W) or water-in-oil (W/O) or multiple (triple: W/O/W or O/W/O) emulsions, of aqueous gels or of dispersions of a fatty phase in an aqueous phase using spherules, it being possible for these spherules to be polymeric nanoparticles, such as nanospheres and nanocapsules, or lipid vesicles of ionic and/or nonionic type (liposomes, niosomes or oleosomes). These compositions are prepared according to the usual methods. [0034]
  • In addition, the compositions used according to the invention can be more or less fluid and can have the appearance of a white or coloured cream, of an ointment, of a milk, of a lotion, of a serum, of a paste or of a foam. They can optionally be applied to the skin in the form of an aerosol. They can also be provided in a solid form, for example in the form of a stick. [0035]
  • When the composition used according to the invention comprises an oily phase, the latter preferably comprises at least one oil. It can additionally comprise other fatty substances. [0036]
  • Mention may be made, as oils which can be used in the composition of the invention, of, for example: [0037]
  • hydrocarbonaceous oils of animal origin, such as perhydrosqualene; [0038]
  • hydrocarbonaceous oils of vegetable origin, such as liquid triglycerides of fatty acids comprising from 4 to 10 carbon atoms, such as triglycerides of heptanoic acid or octanoic acid, or alternatively, for example, sunflower, maize, soybean, gourd, grape seed, sesame, hazelnut, apricot, macadamia, arara, castor or avocado oils, triglycerides of caprylic/capric acids, such as those sold by Stéarineries Dubois or those sold under the names Miglyol 810, 812 and 818 by Dynamit Nobel, jojoba oil, or karite butter oil; [0039]
  • synthetic esters and ethers, in particular of fatty acids, such as the oils of formulae R[0040] 1COOR2 and R1OR2 in which R1 represents the residue of a fatty acid comprising from 8 to 29 carbon atoms and R2 represents a branched or unbranched hydrocarbonaceous chain comprising from 3 to 30 carbon atoms, such as, for example, purcellin oil, isononyl isononanoate, isopropyl myristate, 2-ethylhexyl palmitate, 2-octyldodecyl stearate, 2-octyldodecyl erucate or isostearyl isostearate; hydroxylated esters, such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate or heptanoates, octanoates or decanoates of fatty alcohols; polyol esters, such as propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate; and pentaerythritol esters, such as pentaerythrityl tetraisostearate;
  • linear or branched hydrocarbons of mineral or synthetic origin, such as volatile or nonvolatile liquid paraffins and their derivatives, liquid petrolatum, polydecenes or hydrogenated polyisobutene, such as parleam oil; [0041]
  • fatty alcohols having from 8 to 26 carbon atoms, such as cetyl alcohol, stearyl alcohol and their mixture (cetearyl alcohol), octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleyl alcohol or linoleyl alcohol; [0042]
  • partially hydrocarbon-comprising and/or silicone-comprising fluorinated oils, such as those disclosed in the document JP-A-2-295912; [0043]
  • silicone oils, such as volatile or nonvolatile polymethylsiloxanes (PDMS) comprising a linear or cyclic silicone chain which are liquid or pasty at ambient temperature, in particular cyclopolydimethylsiloxanes (cyclomethicones), such as cyclohexasiloxane; polydimethylsiloxanes comprising pendent alkyl, alkoxy or phenyl groups or alkyl, alkoxy or phenyl groups at the end of the silicone chain, which groups have from 2 to 24 carbon atoms; or phenylated silicones, such as phenyl trimethicones, phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes, (2-phenylethyl)trimethylsiloxysilicates and polymethylphenylsiloxanes; [0044]
  • their mixtures. [0045]
  • The term “hydrocarbonaceous oil” is understood to mean, in the list of the oils mentioned above, any oil predominantly comprising carbon and hydrogen atoms and optionally ester, ether, fluorinated, carboxylic acid and/or alcohol groups. [0046]
  • The other fatty substances which can be present in the oily phase are, for example, fatty acids comprising from 8 to 30 carbon atoms, such as stearic acid, lauric acid, palmitic acid and oleic acid; waxes, such as lanolin, beeswax, carnauba or candelilla wax, paraffin or lignite waxes or microcrystalline waxes, ceresin or ozokerite, or synthetic waxes, such as polyethylene waxes or Fischer-Tropsch waxes; silicone resins, such as trifluoromethyl C[0047] 1-4 alkyl dimethicone and trifluoropropyl dimethicone; and silicone elastomers, such as the products sold under the names “KSG” by Shin-Etsu, under the names “Trefil”, “BY29” or “EPSX” by Dow Corning or under the names “Gransil” by Grant Industries.
  • These fatty substances can be chosen in a way varied by a person skilled in the art in order to prepare a composition having the desired properties, for example of consistency or of texture, in view of this disclosure. [0048]
  • According to a specific embodiment of the invention, the composition according to the invention is a water-in-oil (W/O) or oil-in-water (O/W) emulsion. The proportion of the oily phase in the emulsion can range from 5 to 80% by weight and preferably from 5 to 50% by weight with respect to the total weight of the composition. [0049]
  • The emulsions generally preferably comprise at least one emulsifier selected from the group consisting of amphoteric, anionic, cationic or nonionic emulsifiers, used alone or as a mixture, and optionally a coemulsifier. The emulsifiers are appropriately chosen according to the emulsion to be obtained (W/O or O/W). The emulsifier and the coemulsifier are generally preferably present in the composition in a proportion ranging from 0.3 to 30% by weight and preferably from 0.5 to 20% by weight with respect to the total weight of the composition. [0050]
  • Mention may be made, for the W/O emulsions, for example, as emulsifiers, of dimethicone copolyols, such as the mixture of cyclomethicone and of dimethicone copolyol sold under the name “DC 5225 C” by Dow Corning, and alkyl dimethicone copolyols, such as the laurylmethicone copolyol sold under the name “Dow Corning 5200 Formulation Aid” by Dow Coming and the cetyl dimethicone copolyol sold under the name Abil EM 90[0051] R by Goldschmidt. Use may also be made, as surfactant of W/O emulsions, of a crosslinked solid organopolysiloxane elastomer comprising at least one oxyalkylenated group, such as those obtained according to the procedure of Examples 3, 4 and 8 of the document U.S. Pat. No. 5,412,004 and the examples of the document U.S. Pat. No. 5,811,487, in particular the product of Example 3 (synthetic example) of U.S. Pat. No. 5,412,004, and such as that sold under the reference KSG 21 by Shin Etsu. Use may also be made, as emulsifier, of a polyolefin-derived oligomer or polymer comprising a succinic ending; the latter is preferably a polyolefin comprising an esterified or amidated succinic ending or a salt of such a polyolefin and in particular polyisobutylene comprising an esterified or amidated succinic ending such as the products sold under the names L5603 and L2721 and OS131769 by Lubrizol.
  • Mention may be made, for the O/W emulsions, for example, as emulsifiers, of nonionic emulsifiers, such as esters of fatty acids and of glycerol which are oxyalkylenated (more particularly polyoxyethylenated); esters of fatty acids and of sorbitan which are oxyalkylenated; esters of fatty acids which are oxyalkylenated (oxyethylenated and/or oxypropylenated); ethers of fatty alcohols which are oxyethylenated (oxyethylenated and/or oxypropylenated); sugar esters, such as sucrose stearate; and their mixtures, such as the mixture of glyceryl stearate and of PEG-40 stearate. [0052]
  • The cosmetic or dermatological composition of the invention can also comprise adjuvants known in the cosmetics or dermatological field, such as hydrophilic or lipophilic gelling agents, preservatives, solvents, fragrances, fillers, UV screening agents, bactericides, odour absorbers, colouring materials, plant extracts or salts. The amounts of these various adjuvants are those generally used in the field under consideration, for example from 0.01 to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and/or into the lipid spherules. [0053]
  • Mention may be made, as fillers which can be used in the composition of the invention, for example, of pigments, silica powder; talc; particles of polyamide and in particular those sold under the name Orgasol by Atochem; polyethylene powders; microspheres based on acrylic copolymers, such as those made of ethylene glycol dimethacrylate/lauryl methacrylate copolymer which are sold by Dow Corning under the name Polytrap; expanded powders, such as hollow microspheres and in particular the microspheres sold under the name Expancel by Kemanord Plast or under the name Micropearl F 80 ED by Matsumoto; silicone resin microbeads, such as those sold under the name Tospearl by Toshiba Silicone; and their mixtures. These fillers can be present in amounts ranging from 0 to 20% by weight and preferably from 1 to 10% by weight with respect to the total weight of the composition. [0054]
  • According to a preferred embodiment, the compositions in accordance with the invention can additionally comprise at least one organic photoprotective agent and/or at least one inorganic photoprotective agent which is active in the UV-A and/or UV-B regions (absorbers), and which are soluble in water or in fats or else are insoluble in the cosmetic solvents commonly used. [0055]
  • The organic photoprotective agents are chosen in particular from anthranilates; cinnamic derivatives; dibenzoylmethane derivatives; salicylic derivatives; camphor derivatives; triazine derivatives, such as those disclosed in Patent Applications U.S. Patent No. 4,367,390, EP 863 145, EP 517 104, EP 570 838, EP 796 851, EP 775 698, EP 878 469, EP 933 376, EP 507 691, EP 507 692, EP 790 243 and EP 944 624; benzophenone derivatives; β,β-diphenylacrylate derivatives; benzotriazole derivatives; benzalmalonate derivatives; benzimidazole derivatives; imidazolines; bisbenzoazolyl derivatives as disclosed in Patents EP 669 323 and U.S. Pat. No. 2,463,264; p-aminobenzoic acid (PABA) derivatives; methylenebis(hydroxyphenylbenzotriazole) derivatives as disclosed in Applications U.S. Pat. No. 5,237,071, U.S. Pat. No. 5,166,355, GB 2 303 549, DE 197 26 184 and EP 893 119; screening polymers and screening silicones, such as those disclosed in particular in Application WO 93/04665; dimers derived from α-alkylstyrene, such as those disclosed in Patent Application DE 198 55 649; 4,4-diarylbutadienes as disclosed in Applications EP 0 967 200, DE 197 46 654, DE 197 55 649, EP-A-1 008 586, EP 1 133 980 and EP 133 981; and their mixtures. [0056]
  • By way of illustration, mention may be made, as photoprotective agents which are active in the UV-A and/or UV-B regions, denoted below under their INCI names, of: [0057]
  • p-aminobenzoic acid (PABA) derivatives, in particular PABA, ethyl PABA, ethyl dihydroxypropyl PABA, ethylhexyl dimethyl PABA (sold in particular under the name “Escalol 507” by ISP), glyceryl PABA or PEG-25 PABA (sold under the name “Uvinul P25” by BASF), [0058]
  • salicylic derivatives, in particular homosalate (sold under the name “Eusolex HMS” by Rona/EM Industries), ethylhexyl salicylate (sold under the name “Neo Heliopan OS” by Haarmann and Reimer), dipropylene glycol salicylate (sold under the name “Dipsal” by Scher), or TEA salicylate (sold under the name “Neo Heliopan TS” by Haarmann and Reimer), [0059]
  • dibenzoylmethane derivatives, in particular butyl methoxydibenzoylmethane (sold in particular under the trade name “Parsol 1789” by Hoffmann-LaRoche), or isopropyl dibenzoylmethane, [0060]
  • cinnamic derivatives, in particular ethylhexyl methoxycinnamate (sold in particular under the trade name “Parsol MCX” by Hoffmann-LaRoche), isopropyl methoxycinnamate, isoamyl methoxycinnamate (sold under the trade name “Neo Heliopan E 1000” by Haarmann and Reimer), cinoxate, DEA methoxycinnamate, diisopropyl methyl cinnamate, or glyceryl ethylhexanoate dimethoxycinnamate, [0061]
  • β,β-diphenylacrylate derivatives, in particular octocrylene (sold in particular under the trade name “Uvinul N539” by BASF) or etocrylene (sold in particular under the trade name “Uvinul N35” by BASF), [0062]
  • benzophenone, in particular benzophenone-1 (sold under the trade name “Uvinul 400” by BASF), benzophenone-2 (sold under the trade name “Uvinul D50” by BASF), benzophenone-3 or oxybenzone (sold under the trade name “Uvinul M40” by BASF), benzophenone-4 (sold under the trade name “Uvinul MS40” by BASF), benzophenone-5, benzophenone-6 (sold under the trade name “Helisorb 11” by Norquay), benzophenone-8 (sold under the trade name “Spectra-Sorb UV-24” by American Cyanamid), benzophenone-9 (sold under the trade name “Uvinul DS-49” by BASF), benzophenone-12, or n-hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate, [0063]
  • benzylidene camphor derivatives, in particular 3-benzylidene camphor (manufactured under the name “Mexoryl SD” by Chimex), 4-methylbenzylidene camphor (sold under the name “Eusolex 6300” by Merck), benzylidene camphor sulphonic acid (manufactured under the name “Mexoryl SL” by Chimex), camphor benzalkonium methosulphate (manufactured under the name “Mexoryl SO” by Chimex), terephthalylidene dicamphor sulphonic acid (manufactured under the name “Mexoryl SX” by Chimex), or polyacrylamidomethyl benzylidene camphor (manufactured under the name “Mesoryl SW” by Chimex), [0064]
  • benzimidazole derivatives, in particular phenylbenzimidazole sulphonic acid (sold in particular under the trade name “Eusolex 232” by Merck), or disodium phenyl dibenzimidazole tetrasulphonate (sold under the trade name “Neo Heliopan AP” by Haarmann and Reimer), [0065]
  • triazine derivatives, in particular anisotriazine (sold under the trade name “Tinosorb S” by Ciba Specialty Chemicals), ethylhexyl triazone (sold in particular under the trade name “Uvinul T150” by BASF), diethylhexyl butamido triazone (sold under the trade name “Uvasorb HEB” by Sigma 3V) or 2,4,6-tris(diisobutyl 4′-amino-benzalmalonate)-s-triazine, [0066]
  • benzotriazole derivatives, in particular drometrizole trisiloxane (sold under the name “Silatrizole” by Rhodia Chimie) or methylene bisbenzotriazolyl tetramethylbutylphenol (sold in the solid form under the trade name “Mixxim BB/100” by Fairmount Chemical or in the micronized form in aqueous dispersion under the trade name “Tinosorb M” by Ciba Specialty Chemicals), [0067]
  • anthranilic derivatives, in particular menthyl anthranilate (sold under the trade name “Neo Heliopan MA” by Haarmann and Reimer), [0068]
  • imidazoline derivatives, in particular ethylhexyl dimethoxybenzylidene dioxoimidazoline propionate, [0069]
  • benzalmalonate derivatives, in particular polyorganosiloxane comprising benzalmalonate functional groups (sold under the trade name “Parsol SLX” by Hoffmann-LaRoche), [0070]
  • 4,4-diarylbutadiene derivatives, in particular 1,1′-dicarboxy (2,2′-dimethyl-propyl)-4,4-diphenylbutadiene, [0071]
  • and their mixtures. [0072]
  • The organic photoprotective agents which are more particularly preferred are selected from the group consisting of ethylhexyl salicylate, ethylhexyl methoxycinnamate, octocrylene, phenylbenzimidazole sulphonic acid, benzophenone-3, benzophenone-4, benzophenone-5, 4-methylbenzylidene camphor, terephthalylidene dicamphor sulphonic acid, disodium phenyl dibenzimidazole tetrasulphonate, 2,4,6-tris(diisobutyl 4′-aminobenzalmalonate)-s-triazine, anisotriazine, ethylhexyl triazone, diethylhexyl butamido triazone, methylene bisbenzotriazolyl tetramethylbutylphenol, drometrizole trisiloxane, 1,1′-dicarboxy (2,2′-dimethylpropyl)-4,4-diphenylbutadiene, and their mixtures. [0073]
  • The inorganic photoprotective agents may be selected from the group consisting of pigments or alternatively nanopigments (mean size of the primary particles: generally between 5 nm and 100 nm, preferably between 10 nm and 50 nm) formed from coated or uncoated metal oxides, such as, for example, titanium oxide (amorphous or crystalline in the rutile and/or anatase form), iron oxide, zinc oxide, zirconium oxide or cerium oxide nanopigments, which are all UV photoprotective agents well known per se. Conventional coating agents are, furthermore, alumina and/or aluminium stearate. Such nanopigments formed from coated or uncoated metal oxides are disclosed in particular in Patent Applications EP 518 772 and EP 518 773. [0074]
  • The photoprotective agents are generally present in the compositions according to the invention in proportions ranging from 0.1 to 20% by weight with respect to the total weight of the composition and preferably ranging from 0.2 to 15% by weight with respect to the total weight of the composition. [0075]
  • In another advantageous aspect of the invention, the composition used can additionally comprise at least one other depigmenting or anti-pigmentation active principle in addition to the hydrophilic active principle mentioned above. [0076]
  • The depigmenting or anti-pigmentation agents capable of being incorporated in the composition according to the present invention include, for example, the following compounds: kojic acid; ellagic acid; arbutin and its derivatives, such as those disclosed in Applications EP-895 779 and EP-524 109; hydroquinone; aminophenol derivatives, such as those disclosed in Applications WO 99/10318 and WO 99/32077, in particular N-cholesteryloxycarbonyl-para-aminophenol and N-ethyloxycarbonyl-para-aminophenol; iminophenol derivatives, in particular those disclosed in Application WO 99/22707; L-2-oxothiazolidine-4-carboxylic acid or procysteine, and its salts and esters; ascorbic acid and its derivatives, in particular ascorbyl glucoside and magnesium ascorbyl phosphate; 4-butylresorcinol or lucinol; thiourea and its derivatives; calcium D-pantetheinesulphonate; and plant extracts, in particular extracts of manzanita, of liquorice, of mulberry and of skullcap, without this list being limiting. [0077]
  • The composition according to the invention can be applied to, for example, the skin, hair, including body hair, eyelashes, nails or lips. It can thus be used in a cosmetic treatment process for depigmenting and/or lightening the skin and/or hair, including body hair, comprising the application of the composition according to the invention to the skin and/or hair, including body hair [0078]
  • In an alternative form, the composition according to the invention can be used for the manufacture of a dermatological preparation comprising an aqueous phase which is intended to depigment the skin and/or hair, including body hair. [0079]
  • The examples which follow serve to illustrate the invention without, however, exhibiting a limiting nature. The compounds are, depending on the situation, cited according to chemical names or according to CTFA (International Cosmetic Ingredient Dictionary and Handbook) names. [0080]
  • EXAMPLES Example 1
  • Accelerated Storage Test. [0081]
  • The aim of this test is to study the decomposition of an oxidation-sensitive hydrophilic active principle after storing for two months at 45° C. Various solutions were prepared and their compositions are collated in the following table: [0082]
    TABLE I
    Compositions (in Solution A
    water) (Control) Solution B Solution C Solution D
    Ascorbic acid 15% 15% 15% 15%
    Polymer 1  1%
    Polymer 2  1%
    Polymer 3  1%
  • All the solutions are brought to pH 6 with 8.9 mol/l KOH. [0083]
  • The percentages of the polymers are given as active material. [0084]
  • Polymer 1: Vinylpyrrolidone/vinylimidazole (50/50) copolymer sold under the reference Luvitec VPI 55K72W of BASF (Weight-average molecular mass 1.2×10[0085] 6).
  • Polymer 2: Vinylpyrrolidone/vinylimidazole (50/50) copolymer sold under the reference Luvitec VPI 55K18P of BASF (Weight-average molecular mass 10 000). [0086]
  • Polymer 3: Polyvinylpyrrolidone sold under the reference Kollidon 12PF of BASF (Weight-average molecular mass 3 000). [0087]
  • The degree of decomposition measured is given by the ratio: [0088]
  • (C0-C2 months)/C0
  • with C[0089] 0 concentration of ascorbic acid at t=0 and C2 months the concentration of ascorbic acid at t=2 months, under the conditions indicated in the above table.
  • The concentration of ascorbic acid is determined by the HPLC technique (LaChrom Merck system). The analytical conditions are as follows: [0090]
  • Column: Lichrosphere100 RP18 (250 mm) [0091]
  • Eluent: 0.1 M phosphate buffer, pH 2.1 [0092]
  • Flow rate: 1 ml/min [0093]
  • Detection at 257 nm [0094]
  • Dilution of the sample such that the concentration of ascorbic acid is between 0.05 and 1 mg/ml. [0095]
  • The results obtained are collated in the following Table II: [0096]
    TABLE II
    Degree of decomposition after 2 months at 45° C.
    (in %)
    under air, amber glass
    bottle under nitrogen, aluminium flask
    Solution A 43 19.4
    Solution B 10.8 1
    Solution C 23.4 4.5
    Solution D 35.8 15.7
  • It is found, from Table II, that the stability of ascorbic acid is improved in the presence of Polymer 1 and Polymer 2 of the invention, even in the presence of atmospheric oxygen, in comparison with the control. It is also found that the N-vinylpyrrolidone homopolymer alone is not sufficient to effectively stabilize the ascorbic acid solution. As the polymers mentioned are hydrophilic, it will be sufficient to add them to an aqueous ascorbic acid solution to stabilize the ascorbic acid. [0097]
  • Example 2
  • Demonstration of the Activity With Regard to the Dendricity of Melanocytes: [0098]
  • The aim of this test is to show the effect of the combination of ascorbic acid with a polymer or copolymer according to the invention on adjusting the melanogenesis of human keratinocyte-melanocyte cocultures. [0099]
  • Method: The cells are treated from inoculation with the ascorbic acid/vinylpyrrolidone-vinylimidazole copolymer combinations for 7 days. [0100]
  • Observations: [0101]
  • The melanocytes are labelled using the NK1beteb antibody (green colouring), which recognizes the melanosomes at every stage of maturation. The nuclei of all the cells, melanocytes and keratinocytes, are stained using propidium iodide (red colouring). [0102]
  • Results: [0103]
  • In the absence of the ascorbic acid/vinylpyrrolidone-vinylimidazole copolymer combinations, the melanocytes in cocultures are highly dendritic. The pigment is visibly transferred to the neighbouring keratinocytes. [0104]
  • In the presence of the ascorbic acid/vinylpyrrolidone-vinylimidazole copolymer combinations, the majority of the melanocytes show a reduced dendricity and some melanocytes become bipolar. [0105]
  • For a higher concentration, the majority of the melanocytes are bipolar and the amount of pigment transferred to the keratinocytes is reduced. [0106]
  • Example 3
  • O/W Anti-Blemish Cream [0107]
  • The following composition is prepared in a way conventional to a person skilled in the art. [0108]
    A1 Sorbitan tristearate 0.7 g
    Polyethylene glycol (40 EO) stearate 1.6 g
    Cetyl alcohol 3.2 g
    Glyceryl mono-, di-, tripalmitate/stearate 2.4 g
    Myristyl myristate 2 g
    Liquid fraction of karite butter 2 g
    Preservative 0.2 g
    A2 Cyclopentadimethylsiloxane 15 g
    B Demineralized water 60.53 g
    Glycerol 3 g
    Ascorbic acid 5 g
    50% Potassium hydroxide 3.07 g
    Vinylpyrrolidone/vinylimidazole copolymer 1 g
    Preservative 0.2 g
    C Fragrance 0.1 g
  • This cream which is soft on application makes it possible to reduce pigmentary blemishes and confers good stability on ascorbic acid. [0109]
  • Example 4
  • Depigmenting Gel [0110]
  • The following composition is prepared in a way conventional to a person skilled in the art. [0111]
    Demineralized water 78.58 g
    Polyacrylamide/C13-C14 isoparaffin/Laureth-7 2 g
    (Sepigel 305)
    Silicone oil 10 g
    Ascorbic acid 5 g
    50% Potassium hydroxide 3.07 g
    Vinylpyrrolidone/vinylimidazole copolymer 1 g
    Preservative 0.25 g
    Sequestering agent 0.1 g
  • A fresh gel is obtained, which gel makes it possible to combat cutaneous blemishes and in which gel ascorbic acid has good stability. [0112]
  • The above description of the invention, as illustrated by Examples, allows one of ordinary skill in the art to lighten the skin and/or hair, including body hair, using a composition comprising, in a physiologically acceptable medium comprising an aqueous phase, at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of, e.g., ascorbic acid and its derivatives, and at least one non-crosslinked N-vinylimidazole polymer or copolymer, the said active principle and the said polymer or copolymer both being in the aqueous phase. Also made available is the use of a combination composed of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer in the aqueous phase of a cosmetic composition as agent for lightening the skin and/or hair, including body hair. In addition, this invention makes available the use of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer for the preparation of a dermatological composition comprising an aqueous phase which is intended to depigment the skin and/or hair, including body hair. Similarly made available is the use of a combination composed of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer in the aqueous phase of a cosmetic composition as agent for lightening the skin and/or hair, including body hair, and the use of at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives and of at least one non-crosslinked N-vinylimidazole polymer or copolymer for the preparation of a dermatological composition comprising an aqueous phase which is intended to depigment the skin and/or hair, including body hair. A preferred embodiment of the invention fully described and made available herein is a method for lightening the skin and/or hair, comprising applying thereto a composition comprising a physiologically acceptable medium comprising an aqueous phase; at least one oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives, and at least one non-crosslinked N-vinylimidazole polymer or copolymer, the active principle and the polymer or copolymer both being present in the aqueous phase. [0113]
  • French patent application 0115375 is hereby incorporated by reference, as are all references, texts, documents, standards, applications, patents, etc., mentioned above. [0114]
  • Also incorporated herein by reference are the following U.S. applications, all filed Nov. 27, 2002, where the present application is listed for information only: [0115]
    U.S. Ser. No. . . . (Atty. Docket 230634US0)
    U.S. Ser. No. . . . (Atty. Docket 230608US0)
    U.S. Ser. No. . . . (Atty. Docket 230616US0)
    U.S. Ser. No. . . . (Atty. Docket 230614US0)
    U.S. Ser. No. . . . (Atty. Docket 230615US0)

Claims (15)

1. A method for lightening the skin and/or hair, comprising applying to hair and/or skin to be lightened a composition comprising:
a physiologically acceptable medium comprising an aqueous phase;
at least one lightening oxidation-sensitive hydrophilic active principle selected from the group consisting of ascorbic acid and its derivatives present in an amount sufficient to lighten the skin and/or hair, and:
at least one non-crosslinked N-vinylimidazole polymer or copolymer, the at least one active principle and the at least one polymer or copolymer both being present in the aqueous phase.
2. The method according to claim 1, wherein the hydrophilic active principle is selected from the group consisting of ascorbic acid esters and salts.
3. The method according to claim 1, wherein the hydrophilic active principle is selected from the group consisting of 5,6-di-O-dimethylsilylascorbate, dl-α-tocopheryl dl-ascorbyl phosphate potassium salt, magnesium ascorbyl phosphate and sodium ascorbyl phosphate.
4. The method according to claim 1, wherein the oxidation-sensitive hydrophilic active principle is ascorbic acid.
5. The method according to claim 1, wherein said composition comprises a non-crosslinked copolymer that is a combination of the N-vinylimidazole with N-vinylpyrrolidone and/or N-vinylcaprolactam subunits.
6. The method according to claim 1, wjerein said composition comprises a non-crosslinked N-vinylimidazole/N-vinylpyrrolidone copolymer.
7. The method according to claim 1, wherein the composition comprises a non-crosslinked copolymer selected from the group consisting of a vinylpyrrolidone/vinylimidazole (50/50) copolymer having a weight-average molar mass of 1 200 000 and a vinylpyrrolidone/vinylimidazole (50/50) copolymer having a weight-average molar mass of 10 000.
8. The method according to claim 1, wherein the molar ratio of N-vinylimidazole unit equivalent in said polymer or copolymer to the oxidation-sensitive hydrophilic active principle varies between 0.004 and 16.
9. The method according to claim 8, wherein the molar ratio of the N-vinylimidazole unit equivalent to the oxidation-sensitive hydrophilic active principle varies between 0.01 and 1.
10. The method according to claim 1, wherein the polymer or copolymer is present in said composition in a concentration of from 0.1 to 5% by weight of the aqueous phase.
11. The method according to claim 10, wherein the polymer or copolymer is present at a concentration of between 0.1 and 2% by weight of the aqueous phase.
12. The method according to claim 1, wherein the polymer or copolymer has a molar fraction of N-vinylimidazole units of between 0.1 and 1.
13. The method according to claim 12, wherein the polymer or copolymer has a molar fraction of N-vinylimidazole units of between 0.4 and 0.9.
14. The method according to claim 1, wherein the composition further comprises a depigmenting or anti-pigmentation agent which is different from the oxidation-sensitive hydrophilic active principle.
15. The method according to claim 14, wherein the depigmenting or anti-pigmentation agent is selected from the group consisting of kojic acid; ellagic acid; arbutin and its derivatives; hydroquinone; aminophenols; iminophenols; L-2-oxothiazolidine-4-carboxylic acid or procysteine, and its salts and esters; 4-butylresorcinol or lucinol; thioureas; calcium D-pantetheinesulphonate; ascorbyl glucoside, magnesium ascorbyl phosphate; and plant extracts.
US10/304,861 2001-11-28 2002-11-27 Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer Abandoned US20030124075A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0115375A FR2832630B1 (en) 2001-11-28 2001-11-28 COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE OXIDATION-SENSITIVE HYDROPHILIC ACTIVE STABILIZED WITH AT LEAST ONE COPOLYMER OF N-VINYLIMIDAZOLE
FR0115375 2001-11-28

Publications (1)

Publication Number Publication Date
US20030124075A1 true US20030124075A1 (en) 2003-07-03

Family

ID=8869872

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/304,862 Abandoned US20030125378A1 (en) 2001-11-28 2002-11-27 Composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer useful to prevent and/or treat cutaneous signs of intrinsic ageing
US10/304,860 Expired - Fee Related US7560493B2 (en) 2001-11-28 2002-11-27 Cosmetic and/or dermatological composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer
US10/305,115 Abandoned US20030133889A1 (en) 2001-11-28 2002-11-27 Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylmidazole polymer or copolymer
US10/304,861 Abandoned US20030124075A1 (en) 2001-11-28 2002-11-27 Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer
US10/305,114 Abandoned US20030124161A1 (en) 2001-11-28 2002-11-27 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10/304,862 Abandoned US20030125378A1 (en) 2001-11-28 2002-11-27 Composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer useful to prevent and/or treat cutaneous signs of intrinsic ageing
US10/304,860 Expired - Fee Related US7560493B2 (en) 2001-11-28 2002-11-27 Cosmetic and/or dermatological composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer
US10/305,115 Abandoned US20030133889A1 (en) 2001-11-28 2002-11-27 Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylmidazole polymer or copolymer

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/305,114 Abandoned US20030124161A1 (en) 2001-11-28 2002-11-27 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer

Country Status (11)

Country Link
US (5) US20030125378A1 (en)
EP (5) EP1316302B1 (en)
JP (5) JP3606858B2 (en)
KR (5) KR100514463B1 (en)
CN (5) CN1230148C (en)
AT (1) ATE372109T1 (en)
BR (5) BR0205119A (en)
DE (1) DE60222223T2 (en)
ES (1) ES2292705T3 (en)
FR (1) FR2832630B1 (en)
TW (5) TW200408411A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244352A1 (en) * 2004-04-15 2005-11-03 Cyril Lemoine Cosmetic composition of the water-in-oil emulsion type comprising a deodorant active salt and a polyolefin-derived emulsifier comprising at least one polar part
US20060257352A1 (en) * 2004-06-28 2006-11-16 Ingo Saar Mlv cosmetic product
US20080026019A1 (en) * 2006-06-20 2008-01-31 L'oreal Administration of ellagic acid for the treatment of canities
WO2009014347A2 (en) * 2007-07-20 2009-01-29 G1 Biztech Co., Ltd Stabilized antioxidant-containing particles, process for preparing the same, and composition comprising the same
US10064800B2 (en) 2012-08-29 2018-09-04 Kao Corporation Transglutaminase activator

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
DE10312352A1 (en) * 2003-03-20 2004-09-30 Cognis Deutschland Gmbh & Co. Kg Emollient mixture and its use as a mineral oil substitute
FR2853538B1 (en) * 2003-04-14 2006-06-23 Oreal OIL-WATER EMULSION CONTAINING POLYOLEFIN DERIVATIVE SURFACTANT AND 4,4-DIARYLBUTADIENE, USES
FR2841139B1 (en) * 2003-05-27 2008-03-28 Oreal COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE OXIDATION-HYDROPHILIC ACTIVE STABILIZED BY AT LEAST ONE AMPHIPHILIC POLYMER SELECTED FROM OLIGOMERS OR POLYMERS DERIVED FROM POLYOLEFINS
AU2004253579B2 (en) * 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
DE10331870A1 (en) * 2003-07-14 2005-02-10 Basf Ag Cosmetic and pharmaceutical preparations based on polyelectrolyte complexes
FR2861297B1 (en) * 2003-10-23 2009-04-24 Oreal COSMETIC OR DERMATOLOGICAL H / E EMULSION OF STABLE PH
JP2007527418A (en) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Composition for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2868948B1 (en) * 2004-04-15 2006-05-26 Oreal COSMETIC COMPOSITION OF THE WATER-IN-OIL EMULSION TYPE CONTAINING AN ACTIVE DEODORANT SALT AND A POLYOLEFIN DERIVED EMULSIFIER COMPRISING AT LEAST ONE POLAR PART
EP1593371B1 (en) * 2004-05-05 2011-08-24 Unilever N.V. Acid buffered skin or hair care composition
FR2870455B1 (en) 2004-05-24 2006-06-23 Oreal COSMETIC COMPOSITION COMPRISING PANTETHEIN SULFONIC ACID VESICLES
AU2005262472B2 (en) * 2004-06-16 2011-10-27 President And Fellows Of Harvard College Methods and compositions for modulating bax-mediated apoptosis
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
US20060135383A1 (en) * 2004-12-17 2006-06-22 Cossa Anthony J Cleansing compositions comprising polymeric emulsifiers and methods of using same
DE102005026003A1 (en) * 2005-06-03 2006-12-07 Beiersdorf Ag Cosmetic preparations containing an aqueous aniseed extract and one or more acrylamidomethylpropylsulfonic acid polymers
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
JP2007204399A (en) * 2006-01-31 2007-08-16 Haba Laboratories Inc Water-in-oil type emulsion composition
FR2918561B1 (en) 2007-07-09 2009-10-09 Oreal USE FOR COLORING THE SKIN OF DEHYDROASCORBIC ACID OR POLYMERIC DERIVATIVES; METHODS OF CARE AND / OR MAKE-UP.
US9295621B2 (en) * 2007-07-31 2016-03-29 Elc Management Llc Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant
US20090035236A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent
US8080583B2 (en) * 2007-07-31 2011-12-20 Elc Management Llc Emulsion cosmetic compositions containing resveratrol derivatives and linear or branched silicone
US8344024B2 (en) * 2007-07-31 2013-01-01 Elc Management Llc Anhydrous cosmetic compositions containing resveratrol derivatives
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
WO2009032896A2 (en) * 2007-09-08 2009-03-12 Elc Management Llc Resveratrol ferulate compounds, compositions containing the compounds, and methods of using the same
FR2924609A1 (en) * 2007-12-10 2009-06-12 Lvmh Rech COSMETIC CARE METHOD FOR SENSITIVE SKINS AND COSMETIC COMPOSITIONS FOR SENSITIVE SKIN CARE
FR2930145B1 (en) * 2008-04-16 2012-08-03 Fabre Pierre Dermo Cosmetique USE OF MYRT EXTRACT AS DEPIGMENTING.
JP4687757B2 (en) * 2008-07-22 2011-05-25 株式会社村田製作所 Manufacturing method of multilayer ceramic electronic component
FR2939036B1 (en) 2008-12-01 2010-12-17 Oreal METHOD OF ARTIFICIAL COLORING OF THE SKIN USING A MIXTURE OF CAROTENOID AND LIDOPHILE GREEN COLOR NEW MIXTURE OF LIPOPHILIC COLORANTS; COMPOSITION
JP5373381B2 (en) * 2008-12-18 2013-12-18 ロレアル Cosmetic composition and cosmetic treatment method using the cosmetic composition
FR2940612B1 (en) 2008-12-30 2011-05-06 Oreal ASSOCIATION OF MONOSACCHARIDES WITH ASCORBIC ACID AND ITS USE IN COSMETICS
WO2010077338A1 (en) 2008-12-31 2010-07-08 L'oreal Waving compositions
US8926954B2 (en) * 2009-02-09 2015-01-06 L'oreal S.A. Wave composition containing a bisulfite compound, a sulfate compound, and a phenol
ES2397559T3 (en) * 2009-03-09 2013-03-07 Unilever Nv A cosmetic composition to lighten the skin
KR200454355Y1 (en) * 2009-05-29 2011-06-29 정기옥 Improved fixing device for temper switch
JP6288759B2 (en) * 2012-08-29 2018-03-07 花王株式会社 Transglutaminase activator
DE102013018573A1 (en) 2013-10-31 2015-05-21 Stephan Teichmann Oxidation-stable preparation
KR101833040B1 (en) * 2017-08-28 2018-02-27 (주)대덕랩코 Cosmetic composition comprising physiologically active antioxidant, and two-layered cosmetics comprising the same
CN107625667A (en) * 2017-09-13 2018-01-26 西安瑞捷生物科技有限公司 A kind of basic aqua containing rhamnolipid and preparation method thereof and application
CN108618974B (en) * 2018-06-26 2021-02-05 广州市瓷颜化妆品有限公司 Vitamin C-rich separate mask and preparation method thereof
CN108836890B (en) * 2018-07-06 2021-01-05 广州市瓷颜化妆品有限公司 High-vitamin C content separated facial mask and preparation method thereof
CN112220702B (en) * 2020-10-19 2022-07-12 山东华熙海御生物医药有限公司 Oil phase ectoin clathrate, its preparation method and application
FR3131837A1 (en) 2022-01-19 2023-07-21 L'oreal STABLE COMPOSITION COMPRISING A RETINOID AND AN ASCORBIC ACID COMPOUND
WO2023120390A1 (en) 2021-12-20 2023-06-29 L'oreal Stable composition comprising retinoid and ascorbic acid compound

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531427A (en) * 1967-03-02 1970-09-29 Gaf Corp Stabilized aqueous solutions of alkyl vinyl ether - unsaturated polybasic acid copolymers
US4465629A (en) * 1983-03-17 1984-08-14 Maughan Rex G Method to increase color fastness of stabilized aloe vera
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US5081111A (en) * 1987-03-14 1992-01-14 Nippon Oil And Fats Co., Ltd. Controlled release preparations of active materials
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US5703041A (en) * 1995-07-25 1997-12-30 L'oreal Stable composition containing a water-sensitive cosmetic and/or dermatological active agent
US5801192A (en) * 1995-08-25 1998-09-01 Lvmh Recherche Use of vitamin C or derivatives or analogues thereof promoting skin elastin synthesis
US5891452A (en) * 1996-06-28 1999-04-06 L'oreal Cosmetic or dermatological composition containing at least one active principle precursor and a crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90%
US6008274A (en) * 1992-04-29 1999-12-28 Basf Aktiengesellschaft Stabilization of copolymers of maleic acid or maleic anhydride and vinyl alkyl ethers
US6024942A (en) * 1996-02-09 2000-02-15 The Procter & Gamble Company Photoprotective compositions
US6103267A (en) * 1998-07-27 2000-08-15 Sunsmart, Inc. Stabilized ascorbic acid, composition, and method of use
US6126926A (en) * 1997-01-24 2000-10-03 Kose Corporation Whitening powder
US6162448A (en) * 1997-05-28 2000-12-19 L'oreal Combination of a retinoid with a polyamine polymer
US6191188B1 (en) * 1997-01-14 2001-02-20 Basf Aktiengesellschaft Aqueous compositions and their use
US6232373B1 (en) * 1996-12-18 2001-05-15 Basf Aktiengesellschaft Production and use of formulations consisting of cellulose, kalium caseinate and cross-linked vinylpyrrolidone homopolymers and/or vinylimidazol/vinylpyrrolidone copolymers
US6531160B2 (en) * 2000-05-05 2003-03-11 L′Oreal Microcapsules with an aqueous core containing at least one water-soluble cosmetic or dermatological active principle and cosmetic or dermatological compositions containing them
US6533823B2 (en) * 2000-03-16 2003-03-18 Kao Corporation Dye composition for keratinous fibers
US20030190335A1 (en) * 1997-05-22 2003-10-09 Boudiaf Boussouira Cosmetic use of selected polyamino polymers as antioxidants
US6684530B2 (en) * 2000-01-20 2004-02-03 Asesorfas E Inversiones Santa Francisca Limitada Moisture and temperature regulating insole
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3242051A (en) 1958-12-22 1966-03-22 Ncr Co Coating by phase separation
CA923384A (en) 1970-02-03 1973-03-27 Abe Jinnosuke Process for preparing a micro capsule
US4229430A (en) * 1978-08-21 1980-10-21 Fahim Mostafa S Oral composition for improving oral health
FR2714601B1 (en) 1993-12-30 1996-02-09 Oreal Depigmenting composition for the simultaneous treatment of surface and deep layers, its use.
US5922758A (en) * 1994-09-21 1999-07-13 The Procter & Gamble Company Methods and compositions employing 2,4-dienoic acid esters of tocopherols to prevent or reduce skin damage
FR2736829B1 (en) 1995-07-20 1997-09-12 Oreal COMPOSITION FOR FIGHTING AGAINST SPOTS AND / OR AGING OF THE SKIN, USES THEREOF
DE19640365A1 (en) * 1996-09-30 1998-04-02 Basf Ag Polymer-hydrogen peroxide complexes
US6068847A (en) 1996-10-03 2000-05-30 Johnson & Johnson Consumer Products, Inc. Cosmetic compositions
FR2786391B1 (en) * 1998-11-26 2002-08-02 Oreal HAIRDRESSING COMPOSITION COMPRISING A POLYMER WITH SPECIAL CHARACTERISTICS AND AN IONIC FILM-FORMING POLYMER
MXPA01012189A (en) * 1999-05-26 2002-07-30 Procter & Gamble Detergent compostitions comprising polymeric suds enhancers which have improved mildness and skin feel.
EP1180131A2 (en) * 1999-05-26 2002-02-20 The Procter & Gamble Company Detergent compositions comprising polymeric suds volume and suds duration enhancers
DE19929758A1 (en) * 1999-06-29 2001-01-04 Basf Ag Use of cross-linked cationic polymers in skin cosmetic and dermatological preparations
FR2800274B1 (en) * 1999-10-27 2001-12-07 Oreal ANHYDROUS COMPOSITION CONTAINING A VOLATILE FLUORINATED COMPOUND AND ITS IN PARTICULAR COSMETIC USES
US7838037B2 (en) 1999-11-17 2010-11-23 Tagra Biotechnologies Ltd. Method of microencapsulation
DE10000807A1 (en) * 2000-01-12 2001-07-19 Basf Ag Process for the treatment of a cosmetic agent by irradiation with NIR radiation, and its use
FR2807322B1 (en) * 2000-04-10 2004-02-20 Oreal COMPOSITION, ESPECIALLY COSMETIC, COMPRISING ASCORBIC ACID IN ASSOCIATION WITH AN ASCORBIC ACID DERIVATIVE
DE10023245A1 (en) * 2000-05-12 2001-11-15 Basf Ag Hair sleekening and de-crimping composition free from scalp irritation, containing optionally quaternerized polymer containing cationic monomer, especially N-vinylimidazole or diallylamine
US6468552B1 (en) * 2000-06-02 2002-10-22 Neutrogena Corporation Stabilized compositions containing oxygen-labile active agents
AU2001279820A1 (en) * 2000-08-17 2002-02-25 Basf Aktiengesllschaft Test unit and method for the production of stable formulations
EP1443905A4 (en) * 2001-10-03 2010-06-23 Univ Johns Hopkins Compositions for oral gene therapy and methods of using same
ATE310497T1 (en) 2002-06-20 2005-12-15 Oreal COSMETIC AND/OR DERMATOLOGICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE OXIDATION SENSITIVE HYDROPHILE ACTIVE INGREDIENTS STABILIZED BY AT LEAST ONE POLYMER OR COPOLYMER OF MALEIC ANHYDRIDE
US7105146B2 (en) * 2003-03-04 2006-09-12 Chemco Systems L.P. Method and apparatus for hydration of calcium oxide

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531427A (en) * 1967-03-02 1970-09-29 Gaf Corp Stabilized aqueous solutions of alkyl vinyl ether - unsaturated polybasic acid copolymers
US4465629A (en) * 1983-03-17 1984-08-14 Maughan Rex G Method to increase color fastness of stabilized aloe vera
US5081111A (en) * 1987-03-14 1992-01-14 Nippon Oil And Fats Co., Ltd. Controlled release preparations of active materials
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US6008274A (en) * 1992-04-29 1999-12-28 Basf Aktiengesellschaft Stabilization of copolymers of maleic acid or maleic anhydride and vinyl alkyl ethers
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5703041A (en) * 1995-07-25 1997-12-30 L'oreal Stable composition containing a water-sensitive cosmetic and/or dermatological active agent
US5801192A (en) * 1995-08-25 1998-09-01 Lvmh Recherche Use of vitamin C or derivatives or analogues thereof promoting skin elastin synthesis
US6024942A (en) * 1996-02-09 2000-02-15 The Procter & Gamble Company Photoprotective compositions
US5667791A (en) * 1996-05-31 1997-09-16 Thione International, Inc. X-ray induced skin damage protective composition
US5891452A (en) * 1996-06-28 1999-04-06 L'oreal Cosmetic or dermatological composition containing at least one active principle precursor and a crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90%
US6232373B1 (en) * 1996-12-18 2001-05-15 Basf Aktiengesellschaft Production and use of formulations consisting of cellulose, kalium caseinate and cross-linked vinylpyrrolidone homopolymers and/or vinylimidazol/vinylpyrrolidone copolymers
US6191188B1 (en) * 1997-01-14 2001-02-20 Basf Aktiengesellschaft Aqueous compositions and their use
US6126926A (en) * 1997-01-24 2000-10-03 Kose Corporation Whitening powder
US20030190335A1 (en) * 1997-05-22 2003-10-09 Boudiaf Boussouira Cosmetic use of selected polyamino polymers as antioxidants
US6162448A (en) * 1997-05-28 2000-12-19 L'oreal Combination of a retinoid with a polyamine polymer
US6103267A (en) * 1998-07-27 2000-08-15 Sunsmart, Inc. Stabilized ascorbic acid, composition, and method of use
US6684530B2 (en) * 2000-01-20 2004-02-03 Asesorfas E Inversiones Santa Francisca Limitada Moisture and temperature regulating insole
US6533823B2 (en) * 2000-03-16 2003-03-18 Kao Corporation Dye composition for keratinous fibers
US6531160B2 (en) * 2000-05-05 2003-03-11 L′Oreal Microcapsules with an aqueous core containing at least one water-soluble cosmetic or dermatological active principle and cosmetic or dermatological compositions containing them

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244352A1 (en) * 2004-04-15 2005-11-03 Cyril Lemoine Cosmetic composition of the water-in-oil emulsion type comprising a deodorant active salt and a polyolefin-derived emulsifier comprising at least one polar part
US20060257352A1 (en) * 2004-06-28 2006-11-16 Ingo Saar Mlv cosmetic product
US20080026019A1 (en) * 2006-06-20 2008-01-31 L'oreal Administration of ellagic acid for the treatment of canities
WO2009014347A2 (en) * 2007-07-20 2009-01-29 G1 Biztech Co., Ltd Stabilized antioxidant-containing particles, process for preparing the same, and composition comprising the same
WO2009014347A3 (en) * 2007-07-20 2009-03-12 G1 Biztech Co Ltd Stabilized antioxidant-containing particles, process for preparing the same, and composition comprising the same
US10064800B2 (en) 2012-08-29 2018-09-04 Kao Corporation Transglutaminase activator

Also Published As

Publication number Publication date
US20030124161A1 (en) 2003-07-03
BR0205122A (en) 2004-06-29
DE60222223T2 (en) 2008-05-29
CN1421197A (en) 2003-06-04
EP1316304A1 (en) 2003-06-04
JP2003160467A (en) 2003-06-03
KR100524240B1 (en) 2005-10-26
JP2003160466A (en) 2003-06-03
JP3655276B2 (en) 2005-06-02
FR2832630B1 (en) 2005-01-14
ES2292705T3 (en) 2008-03-16
CN1421194A (en) 2003-06-04
JP2003160426A (en) 2003-06-03
TW200304831A (en) 2003-10-16
CN1187035C (en) 2005-02-02
CN1228039C (en) 2005-11-23
CN1230148C (en) 2005-12-07
KR20030043765A (en) 2003-06-02
JP2003160431A (en) 2003-06-03
KR100514463B1 (en) 2005-09-14
KR20030043763A (en) 2003-06-02
DE60222223D1 (en) 2007-10-18
TW200303764A (en) 2003-09-16
JP3606858B2 (en) 2005-01-05
EP1316305A1 (en) 2003-06-04
KR20030043766A (en) 2003-06-02
TW200408411A (en) 2004-06-01
TW200303760A (en) 2003-09-16
BR0205120A (en) 2004-06-29
JP3606857B2 (en) 2005-01-05
FR2832630A1 (en) 2003-05-30
US20030143275A1 (en) 2003-07-31
CN1421195A (en) 2003-06-04
KR20030043767A (en) 2003-06-02
EP1316302A1 (en) 2003-06-04
KR100514465B1 (en) 2005-09-14
US20030125378A1 (en) 2003-07-03
JP3606859B2 (en) 2005-01-05
JP3606856B2 (en) 2005-01-05
CN1421193A (en) 2003-06-04
US7560493B2 (en) 2009-07-14
BR0205135A (en) 2004-06-29
KR100514464B1 (en) 2005-09-13
EP1316306A1 (en) 2003-06-04
CN1200687C (en) 2005-05-11
BR0205119A (en) 2004-06-29
TW200303763A (en) 2003-09-16
EP1316302B1 (en) 2007-09-05
KR20030043764A (en) 2003-06-02
JP2003160429A (en) 2003-06-03
US20030133889A1 (en) 2003-07-17
CN1421196A (en) 2003-06-04
BR0205152A (en) 2004-06-29
ATE372109T1 (en) 2007-09-15
EP1316303A1 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
US7803354B2 (en) Cosmetic and/or dermatological use of a composition comprising at least one oxidation-sensitive hydrophilic active principle stabilized by at least one maleic anhydride copolymer
US20030124075A1 (en) Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer
US20040096406A1 (en) Composition containing ascorbic acid compound and screening agent, method of use
WO2004028483A2 (en) Cosmetic or dermatological composition containing an ascorbic acid derivative and a filter

Legal Events

Date Code Title Description
AS Assignment

Owner name: L'OREAL, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BIATRY, BRUNO;LHEUREUX, ERIC;REEL/FRAME:013814/0624

Effective date: 20030123

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION